健康元：公司通过控股子公司丽珠集团间接持有新元素药业的股权比例较低

Core Viewpoint - The company holds a 6.1% stake in New Element Pharmaceuticals through its subsidiary, Lizhu Group, which is classified as a long-term equity investment. The listing of New Element Pharmaceuticals on the Hong Kong Stock Exchange is not expected to have a significant financial impact on the company [1]. Group 1 - The company indirectly holds a 6.1% stake in New Element Pharmaceuticals through its subsidiary, Lizhu Group, which has a 47.18% ownership [1]. - The investment in New Element Pharmaceuticals is categorized as a long-term equity investment [1]. - The successful listing of New Element Pharmaceuticals will not have a major financial impact on the company [1].